Phathom Pharmaceuticals, Inc. (PHAT) closed the last trading session at $10.95, gaining 21% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $20.5 indicates an 87.2% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $8.02. While the lowest estimate of $5.00 indicates a 54.3% decline from the current price level, the most optimis ...

Financial Data and Key Metrics Changes - The company reported net revenues of $39.5 million for Q2 2025, representing a 39% increase compared to Q1 2025, driven by increased adoption of Vopresna [24][17] - Non-GAAP operating expenses for Q2 2025 were $86.1 million, a decrease of $12 million from Q1 2025, reflecting early cost-saving initiatives [25][26] - The company ended the quarter with approximately $150 million in cash, which is expected to support operations until profitability in 2026 [29][18] Business Line Data and Key Metrics Changes - Over 580,000 Vopresna prescriptions have been filled since launch, with a 49% growth in the last fourteen weeks [6] - In Q2, approximately 173,000 prescriptions were filled, reflecting a 36% growth over Q1 [7] - 68% of Q2 Vopresna prescriptions were filled through the retail channel, with a slight decrease due to the rollout of a cash pay option for Medicare patients [7][8] Market Data and Key Metrics Changes - Commercial access remains above 80% of lives covered, with more than half requiring only a single step edit or less [7] - The company has seen a 24% increase in unique healthcare providers (HCPs) writing Vopresna prescriptions compared to Q1 [8] Company Strategy and Development Direction - The company is focusing on gastroenterologists as the primary target for sales efforts, believing this will lead to accelerated revenue growth [11][12] - A phase two trial in eosinophilic esophagitis (EOE) is set to begin in Q4 2025, which may provide a path to extend exclusivity [16][17] - The company anticipates revenue guidance of $165 to $175 million for the full year 2025, above current analyst estimates [18][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability by 2026, emphasizing the importance of Vopresna as a treatment option for GERD patients who do not respond to PPIs [21][30] - The company is committed to financial discipline while continuing to invest in key areas driving revenue growth [30][31] Other Important Information - The FDA has updated the orange book to reflect exclusivity for Vopresna through May 2032, enhancing the net present value (NPV) of the product [15] - The company has implemented cost-saving initiatives that have already shown a $12 million reduction in non-GAAP operating expenses compared to Q1 2025 [25][26] Q&A Session Summary Question: How will the sales force drive more depth and frequency of writing prescriptions? - The sales force has realigned territories to focus on gastroenterologists, dropping over 20,000 primary care physicians who had not converted [34][35] - Increased call frequency with gastroenterologists is expected to lead to higher prescription writing [36][38] Question: Is the anticipated revenue acceleration already included in the current guidance? - Management believes long-term acceleration is a driver to the upside, but it may take one to three quarters for the new targeting strategy to show consistent growth [41][42] Question: What is the tipping point for transitioning from gastroenterologists to primary care physicians? - Management indicated that significant revenue potential exists within the GI market alone, and primary care is viewed as an additive opportunity [50][51] Question: How are cost cuts being implemented and their impact on growth? - Major cost savings are coming from eliminating direct-to-consumer promotional programs and adjusting third-party vendor contracts [59][62] Question: What is the current average cash pay amount through BlinkRx? - The standard cash pay amount through BlinkRx is $50, with a $25 copay for insured patients [93][95]

Business Update Steven Basta, President & Chief Executive Officer Q2 2025 Financial Results Robert Breedlove, VP of Finance & Principal Accounting Officer Closing Remarks SECOND QUARTER 2025 EARNINGS CONFERENCE CALL AUGUST 2025 NASDAQ: PHAT Today's Agenda Steven Basta, President & Chief Executive Officer Question & Answer Steven Basta, President & Chief Executive Officer Robert Breedlove, VP of Finance & Principal Accounting Officer 2 Safe harbor This presentation contains forward-looking statements. All st ...

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements (unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) Unaudited statements show rising product revenue but continued net losses and a widening stockholders' deficit [Condensed Balance Sheets](index=3&type=section&id=Condensed%20Balance%20Sheets) The balance sheet reflects a significant decrease in cash and a widening stockholders' deficit to $405.8 million Condensed Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $149,569 | $297,263 | | Total current assets | $218,875 | $360,134 | | Total assets | $250,220 | $378,318 | | Total current liabilities | $91,823 | $85,728 | | Total liabilities | $656,054 | $631,898 | | Total stockholders' deficit | $(405,834) | $(253,580) | [Condensed Statements of Operations and Comprehensive Loss](index=4&type=section&id=Condensed%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Q2 2025 saw a surge in product revenue to $39.5 million, though the net loss remained high at $75.8 million Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Product revenue, net | $39,503 | $7,324 | $68,023 | $9,236 | | Gross profit | $34,465 | $5,948 | $59,261 | $7,434 | | Total operating expenses | $94,389 | $83,248 | $198,047 | $154,688 | | Loss from operations | $(59,924) | $(77,300) | $(138,786) | $(147,254) | | Net loss | $(75,810) | $(91,446) | $(170,126) | $(174,298) | | Net loss per share | $(1.05) | $(1.56) | $(2.36) | $(2.98) | [Condensed Statements of Cash Flows](index=6&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) Net cash used in operations increased to $147.7 million for the first six months of 2025 Cash Flow Summary for Six Months Ended June 30 (in thousands) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(147,659) | $(139,741) | | Net cash used in investing activities | $(115) | $(86) | | Net cash provided by financing activities | $80 | $34,671 | | **Net decrease in cash** | **$(147,694)** | **$(105,156)** | [Notes to Condensed Unaudited Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Unaudited%20Financial%20Statements) Notes detail the VOQUEZNA launch, debt obligations, and a May 2025 restructuring plan - The FDA approved VOQUEZNA for Erosive GERD and H. pylori in late 2023, with commercial launch in Q4 2023, and an additional approval for Non-Erosive GERD was granted on **July 17, 2024**[22](index=22&type=chunk) - Management believes it has **sufficient working capital** to fund operations through at least the next twelve months from the issuance date of the financial statements[25](index=25&type=chunk) - For the first six months of 2025, **three customers accounted for 72% of product sales** and represented 82% of the accounts receivable balance as of June 30, 2025[38](index=38&type=chunk) - In May 2025, the company implemented a restructuring plan, reducing its workforce by 28 employees (approx. 6%) and incurring **total charges of $8.0 million**[104](index=104&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management highlights the strong VOQUEZNA launch, rising revenues, and sufficient liquidity for the next year [Overview](index=24&type=section&id=Overview) The company's focus is on commercializing VOQUEZNA, which shows strong prescription momentum post-launch - As of July 25, 2025, **over 580,000 prescriptions** for VOQUEZNA products have been filled by more than 29,300 prescribers since launch[110](index=110&type=chunk) - On July 17, 2024, the FDA approved VOQUEZNA 10 mg tablets for the relief of heartburn associated with **Non-Erosive GERD**[109](index=109&type=chunk) - The company has been informed of a potential supply disruption for clarithromycin, a component of VOQUEZNA TRIPLE PAK, which accounts for **approximately 1% of total revenue**[113](index=113&type=chunk) [Results of Operations](index=29&type=section&id=Results%20of%20Operations) Q2 2025 revenue surged to $39.5 million, with increased SG&A expenses driven by launch and restructuring costs Comparison of Three Months Ended June 30 (in thousands) | Account | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Product revenue, net | $39,503 | $7,324 | $32,179 | | Research and development | $9,076 | $7,376 | $1,700 | | Selling, general and administrative | $85,313 | $75,872 | $9,441 | | Net loss | $(75,810) | $(91,446) | $15,636 | Comparison of Six Months Ended June 30 (in thousands) | Account | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Product revenue, net | $68,023 | $9,236 | $58,787 | | Research and development | $18,260 | $16,806 | $1,454 | | Selling, general and administrative | $179,787 | $137,882 | $41,905 | | Net loss | $(170,126) | $(174,298) | $4,172 | - The **$41.9 million increase in SG&A** for the first six months of 2025 was primarily due to a $32.5 million increase in advertising and promotional expenses for the VOQUEZNA launch and an $8.9 million increase in personnel-related expenses from restructuring[137](index=137&type=chunk) [Liquidity and Capital Resources](index=32&type=section&id=Liquidity%20and%20Capital%20Resources) The company holds $149.6 million in cash and believes it has sufficient capital to fund operations for one year - The company had **cash and cash equivalents of $149.6 million** as of June 30, 2025[139](index=139&type=chunk) - The company has a term loan agreement with Hercules, which was amended to increase the principal amount up to $300 million, but **does not expect to meet the revenue threshold** to draw the final $50 million tranche[144](index=144&type=chunk)[150](index=150&type=chunk) - The Revenue Interest Financing Agreement entitles investors to a **10% royalty on net sales** of vonoprazan products until they receive aggregate payments equal to 200% of their investment[156](index=156&type=chunk) Cash Flow Summary for Six Months Ended June 30 (in thousands) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(147,659) | $(139,741) | | Net cash used in investing activities | $(115) | $(86) | | Net cash provided by financing activities | $80 | $34,671 | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=40&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Market risk exposures remain materially unchanged from the 2024 Form 10-K disclosures - There have been **no material changes** to the company's market risk since the disclosures in the 2024 Form 10-K[176](index=176&type=chunk) [Item 4. Controls and Procedures](index=40&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2025 - Management evaluated disclosure controls and procedures and concluded **they were effective** as of June 30, 2025[178](index=178&type=chunk) - **No material changes** in internal control over financial reporting occurred during the second quarter of 2025[179](index=179&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=42&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no current involvement in any material legal proceedings - The company is **not currently a party** to any material legal proceedings[181](index=181&type=chunk) [Item 1A. Risk Factors](index=42&type=section&id=Item%201A.%20Risk%20Factors) Risk factors remain materially unchanged from those disclosed in the 2024 Annual Report - **No material changes** have occurred to the risk factors disclosed in the 2024 Form 10-K[182](index=182&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=42&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities or issuer repurchases occurred during the period - There were **no unregistered sales of equity securities** or issuer repurchases of equity securities in the reported period[183](index=183&type=chunk)[184](index=184&type=chunk) [Item 6. Exhibits](index=43&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed, including new executive separation and employment agreements - The report includes several exhibits, such as **separation agreements** with Azmi Nabulsi and Molly Henderson, and an employment letter with Anne Marie Cook[190](index=190&type=chunk)

Exhibit 99.1 Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates FLORHAM PARK, N.J., August 7, 2025 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter ended June 30, 2025, and provided business updates. "The second quarter marked a significant step forward in Phathom's journey toward bec ...

Core Insights - Phathom Pharmaceuticals reported significant revenue growth in Q2 2025, with net revenues of $39.5 million, up from $7.3 million in Q2 2024, driven by the commercial success of VOQUEZNA products [5][6][11] - The company aims to achieve profitability by 2026, supported by a refined commercial strategy focusing on high-value prescribers and strong prescription trends [2][6][11] Business Highlights - Over 580,000 VOQUEZNA prescriptions have been filled to date, reflecting a 49% increase since the last earnings report [6][7] - Approximately 173,000 VOQUEZNA prescriptions were filled in Q2 2025, representing a 36% sequential growth from Q1 2025 [7] - The prescriber base has expanded, with over 29,300 unique healthcare providers writing prescriptions, a 24% increase since the last quarterly update [7] Financial Performance - R&D expenses for Q2 2025 were $9.1 million, an increase from $7.4 million in Q2 2024, primarily due to one-time restructuring charges [11] - SG&A expenses rose to $85.3 million in Q2 2025 from $75.9 million in Q2 2024, driven by higher personnel-related costs [11] - The net loss for Q2 2025 was $75.8 million, compared to $91.4 million in Q2 2024, with a non-GAAP adjusted net loss of $56.5 million [11][19] Market Position and Strategy - The FDA granted 10-year New Chemical Entity exclusivity for VOQUEZNA, extending market protection until May 2032, which is expected to delay generic competition until at least 2033 [7] - The company has shifted its sales strategy to prioritize gastroenterologists over primary care physicians to enhance prescriber engagement [7] Future Outlook - Phathom expects full-year 2025 revenue to be between $165 million and $175 million, based on strong prescription trends and a refined commercial strategy [6][11] - The company anticipates non-GAAP operating expenses to decrease to less than $60 million in Q3 2025 and less than $55 million in Q4 2025 [11]

Group 1 - The company has a strong academic foundation with an MBA in Finance and an MD, enhancing its expertise in the financial sector [1] - The company operates as a registered investment advisor and professional money manager, focusing on income investing and biotech/pharma investing [2] - The company emphasizes community building for sharing and thriving breakthrough investment ideas in the biotech/pharma industry [2] Group 2 - The company provides in-depth analysis of income investing and long-term takeover potential biotech/pharma stocks, identifying both short-term and long-term investment opportunities [3] - The company offers tailored biotech analysis and regular portfolio trade alerts, facilitating investor engagement and confidence in navigating biotech investments [4] - The company has authored a top-selling book on biotech investing and provides educational resources through an online course [4]

Business Overview - VOQUEZNA aims to transform the landscape of acid-related disorders, targeting a US potential peak revenue opportunity of over $3 billion[11, 12] - The company is experiencing early success with its pricing and access strategy[20] - VOQUEZNA launch is off to a strong start, with over 14,000 total demand[18] Commercial Launch Progress - Over 3,800 filled VOQUEZNA scripts[18] - Over 1,200 unique VOQUEZNA writers[18] - The company has achieved approximately 38% commercial coverage, representing about 60 million commercial lives covered[21] Financial Results - The company had $3814 million in cash as of December 31, 2023[27] - Q4 2023 net revenues were $07 million[27] - Full Year 2023 Non-GAAP R&D expenses were $714 million, and Non-GAAP SG&A expenses were $1010 million[27] - Full Year 2023 GAAP net loss was ($201592) thousand, and Non-GAAP adjusted net loss was ($129713) thousand[29]

Business Update - VOQUEZNA has achieved significant progress in clinical superiority, brand awareness, and patient access during its launch phase[10] - As of April 26, 2024, over 43,000 prescriptions have been written and over 17,500 prescriptions have been filled for VOQUEZNA[12] - VOQUEZNA has secured commercial coverage for approximately 72 million lives[13] - The company is preparing for a potential Non-Erosive GERD launch, with an action date of July 19, 2024, targeting a market of approximately 15 million adults[14] Commercial Launch Progress - Total VOQUEZNA demand includes over 43,000 unique prescriptions written and over 17,500 filled prescriptions[21] - The number of unique VOQUEZNA writers has reached over 3,800[21] - There has been consistent monthly growth in filled prescriptions, reaching approximately 7,520 as of April 26, 2024[26] - Commercial coverage has expanded to 48%, covering approximately 72 million lives, including Cigna Healthcare with over 9 million lives covered[28] Financial Results - Net revenues for Q1 2024 were $1.9 million[36] - Non-GAAP SG&A expenses for Q1 2024 were $57.6 million[40] - The company reported $322.2 million in cash and cash equivalents as of March 31, 2024, which is expected to fund operations through the end of 2026[43]

Business & Product Updates - VOQUEZNA prescriptions filled reached over 143,000[9, 21] - Commercial coverage expanded to over 120 million lives[9, 25] - The company successfully completed an equity follow-on, raising $130 million in gross proceeds[9] - Three VOQUEZNA products are approved across three indications[14] Commercial Launch Progress - Filled prescriptions grew significantly in Q3 2024, reaching approximately 69,000, a ~100% increase compared to Q2 2024[20] - Cumulative writers increased to over 12,400 in Q3 2024, a ~70% increase compared to Q2 2024[24] - Over 80% commercial coverage has been established[25] Financial Results - Net revenues for Q3 2024 were $16.4 million[33, 35] - Non-GAAP SG&A expenses were $71.8 million in Q3 2024[37] - Non-GAAP R&D expenses were $7.4 million in Q3 2024[37] - Adjusted net loss for Q3 2024 was $67.85 million, or $1.05 per share[39] - Cash and cash equivalents totaled $334.7 million as of September 30, 2024[40]